Phaseline

Companies › Amneal Pharmaceuticals

Amneal Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 17 registered trials: 10 Phase 2, 4 Phase 4, 2 Phase 1, 1 Phase 3; Neurology, Genitourinary, Metabolic and endocrine, Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Testosterone Cypionate
Androgen Receptor agonist
ARPhase 3Male Hypogonadism; Weaning Failure; Transgenderism; Localized Prostate Carcinoma …Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06592144Testosterone CypionatePhase 4Weaning FailureNeurologyAug 2026
NCT06111209Testosterone CypionatePhase 2Stress Urinary IncontinenceGenitourinaryDec 2026
NCT04731376Testosterone CypionatePhase 1HypogonadismOncologyDec 2026
NCT06059118Testosterone CypionatePhase 2Prostate CancerOncologyJan 2027
NCT07898072Testosterone CypionatePhase 3Male HypogonadismMetabolic and endocrineMar 2027
NCT04363164Testosterone CypionatePhase 2Castration Resistant Metastatic Prostate CancerOncologyJul 2027
NCT06392295Testosterone CypionatePhase 2Prostate CancerOncologyAug 2027
NCT06392295Testosterone CypionatePhase 2Prostate CancerOncologyAug 2027
NCT07476001Testosterone CypionatePhase 2Metastatic Castration-resistant Prostate CancerOncologySep 2027
NCT04798469Testosterone CypionatePhase 2Opioid UsePsychiatrySep 2027
NCT06100705Testosterone CypionatePhase 2Metastatic Castration-resistant Prostate CancerOncologyDec 2027
NCT04704505Testosterone CypionatePhase 2Prostate AdenocarcinomaOncologyFeb 2028
NCT06305598Testosterone CypionatePhase 1Castration-Resistant Prostate CarcinomaOncologyMar 2028
NCT07092527Testosterone CypionatePhase 4TransgenderismPsychiatryNov 2028
NCT06733350Testosterone CypionatePhase 4Localized Prostate CarcinomaOncologyJan 2029
NCT07142551Testosterone CypionatePhase 2Metastatic Castration-resistant Prostate CancerOncologyJun 2030
NCT07278362Testosterone CypionatePhase 4Prostate CancerOncologyMay 2031

From the company's SEC filings

Cash of $157m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

AR (1)

Companies with the same targets

Johnson & Johnson (Janssen) Novartis Astellas Alessa Therapeutics Sun Pharmaceutical Industries Hansoh BioMedical R&D Company Merck & Co. (MSD) Bayer Qilu Pharmaceutical Aragon Pharmaceuticals

Companies built like this

Aragon Pharmaceuticals Tolmar Halozyme Therapeutics Lipocine Upsher-Smith Laboratories

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.